


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

PATENT  
Attorney Docket No.: 20695D-000110US  
Client Reference No.: US 196



on May 13, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Maisie C. Livengood  
Maisie C. Livengood

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Mitterer, et al.

Application No.: 10/003,621

Filed: November 2, 2001

For: A Method for Purifying Factor vWF-  
Complex by Means of Cation Exchange  
Chromatography

Examiner:

Art Unit: 1653

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR  
§1.97 and §1.98

**RECEIVED**  
MAY 19 2003  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/367,459, filed August 13, 1999 (Attorney Docket No. 20695D-000100US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Please note that some of the references are not in English but an English language equivalent is provided for these references as noted in the chart below and as noted on the form PTO/SB/08B.

Document No.	Translation No.
DE 35 04 385	US 4,578,218
EP 0 416 983	US 5,679,776
EP 0 714 987	US 5,858,658
EP 0 714 988	US 5,789,153
WO 93/15199	US 5,876,969
WO 96/10584	US 5,877,152
WO 97/34930	US 6,228,613
WO 97/39033	CA 2,251,558
WO 98/38219	AU 737986

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:mcl  
DE 7084203 v1



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1

of 2

### Complete if Known

Application Number	10/003,621
Filing Date	November 2, 2001
First Named Inventor	Mitterer, Artur
Art Unit	1653
Examiner Name	
Attorney Docket Number	20695D-000110US

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
[Signature]	AA	4,578,218		03-25-1986	Saundry et al.	530/383 260/112
	AB	5,679,776		10-21-1997	Burmouf-Radosovich et al.	435/16 435/5
	AC	5,789,153		08-04-1998	Falkner et al.	435/16 435/69.7
	AD	5,858,658		01-12-1999	Haemmerle et al.	514/12 530/383
	AE	5,876,969		03-02-1999	Fleer et al.	514/12 435/69.1
	AF	5,877,152		03-02-1999	Fischer et al.	
	AG	5,880,265		03-09-1999	Fischer et al.	
	AH	6,103,693		08-15-2000	Fischer et al.	
	AI	US-6,228,613 B1		05-08-2001	Fischer et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				
[Signature]	AJ	AU	737986	B2	09-0602001			
	AK	CA	2,251,558		10-09-1998			
	AL	DE	35 04 385	A1	08-14-1985			
	AM	EP	0 131 740	B1	10-31-1985			
	AN	EP	0 295 645	A2	12-21-1988			
	AO	EP	0 416 983	B1	03-13-1991			
	AP	EP	0 600 480	A2	06-08-1994			
	AQ	EP	0 714 987	A2	06-05-1996			
	AR	EP	0 714 988	A2	06-05-1996			
	AS	WO	91/13093		09-05-1991			
	AT	WO	93/15199		08-05-1993			
	AU	WO	96/10584		04-11-1996			
	AV	WO	97/34930		09-25-1997			
	AW	WO	97/39033		10-23-1997			
	AX	WO	98/38219		09-03-1998			

RECEIVED  
MAY 19 2003  
TECH CENTER 1600/2900


Examiner Signature	[Signature]	Date Considered	12/5/03
-----------------------	-------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DE 7084203 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/003,621		
		Filing Date	November 2, 2001		
		First Named Inventor	Mitterer, Artur		
		Art Unit	1653		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	20695D-000110US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
HK	AY	Official Action for A 338/97, dated 01 Sep. 1997	
	AZ	Official Action for A 338/97, dated 17 September 1997	
	BA	Official Action for A 866/98, dated 20 May 1998	
	CB	International Search Report for PCT/AT 98/00043	
	CC	BERNTORP, E.; Plasma Product Treatment in Various Types of von Willebrand's Disease"; <i>Haemostasis</i> ; 1994; pp. 289-297; Vol 24	
	CD	BOURGOIS, A. et al.; "Blood-coagulation Factor (vWF) Complex"; <i>Chem. Abs</i> ; 1986; p. 380; Vol. 105; Abstract No. 178421n	
	CE	HARRISON, R.H., et al.; "Chromatography of the VIII/vWF Complex on Dextran Sulphate Sepharose"; <i>Thromb. Res.</i> ; 1988; pp. 295-304; Vol. 50	
	CF	HARRISON, P., et al.; The Purification of the VIII/vWF Complex Using Dextran Sulfate Sepharose Chromatography"; <i>Chem. Abs.</i> ; 1990; p. 274; ; Vol. 112; Abstract No. 11822b	
	CG	KOOPS, et al.; "Immunoaffinity Purification of Factor VIII/von Willebrand Factor Complex"; <i>Chem Abs.</i> ; 1992; p. 324; Vol. 117; Abstract No. 3089f	
	CH	LETHAGEN, et al.; Pharmacokinetics and Hemostatic Effect of Different Factor VIII/von Willebrand Factor Concentrates in von Willebrand's Disease Type III"; <i>Ann. Hematol.</i> , 1992; pp. 253-259; Vol. 65	
	CI	MEJAN, O. et al.; "Immunopurification of Human Factor VIII/vWF Complex From Plasma; <i>Pharmaceuticals</i> ; 1983; p. 357; Vol. 109; Abstract No. 115910h.	
	CJ	RUTTYN, Y. et al.; Chromatography of Human Plasma on Aminohexyl Sepharose: Separation of Factor VIII/vWF and Behavior of Factors II, VII, IX and X and Antithrombin III"; <i>Enzymes</i> ; 1989; p. 311; Vol. 111; Abstract No. 149359s.	
	CK	SAUNDY et al.; "The Interaction of the Factor VIII/von Willebrand Factor Complex with Immobilized Metal Affinity Chromatography (IMAC) Matrixes"; <i>Biochem Methods</i> ; 1990; p. 252; ; Vol. 112; Abstract No. 18400w.	

Examiner Signature		Date Considered	12/1/03
-----------------------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
DE 7084203 v1